Arca
Skip to content

Aging

Drug research and approvals for aging: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 570 studies of aging are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 570
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 570 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

5 in phase 3, 17 in phase 2, 22 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Metformin
Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Testosterone undecanoate
Phase 3 Androgen Receptor agonist
Prasterone
Phase 3 Unknown
Ivabradine
Phase 3 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
Sirolimus
Phase 2 FK506-binding protein 1A inhibitor
Dasatinib anhydrous
Phase 2 Tyrosine-protein kinase ABL inhibitor
Acarbose
Phase 2 Pancreatic alpha-amylase inhibitor
Influenza virus vaccine
Phase 2 Biological vaccine - induces immune response
Quercetin
Phase 2
Oxytocin
Phase 2 Oxytocin receptor agonist
Somatropin
Phase 2 Growth hormone receptor agonist
Cholecalciferol
Phase 2 Vitamin D receptor agonist
Capromorelin
Phase 2 Ghrelin receptor agonist
Oxygen
Phase 2 Essential for cellular homeostasis
Ghrelin
Phase 2
Testosterone
Phase 1 Androgen Receptor agonist
Nicotine
Phase 1 Neuronal acetylcholine receptor; alpha4/beta2 agonist
Diclofenac
Phase 1 Cyclooxygenase inhibitor
Everolimus
Phase 1 FK506-binding protein 1A inhibitor
Losartan
Phase 1 Type-1 angiotensin II receptor antagonist
Nitroprusside
Phase 1 Soluble guanylate cyclase activator
Anastrozole
Phase 1 Cytochrome P450 19A1 inhibitor
Mecamylamine
Phase 1 Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator

Showing the 30 furthest along of 44 in trials.

Trials Authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Aug 29, 2013"a single blind, split-face, randomized, pilot study to compare the effects of intradermal & intramuscular treatments with two commercially available botulinum…Botox cosmetic (onabotulinumtoxin a)Institute Of Cosmetic & Laser SurgeryPending

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 27, 2019NuceivaBotulinum toxin type aEvolus Pharma B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.